Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Statera Biopharma, Inc. (STAB)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
2537 Research Boulevard 80526
Fort Collins, CO, US
Fort Collins, CO, US
CEO
Blake Hawley
Website
staterabiopharma.com
IPO
2021-07-28
CIK 1318641 ISIN US8575611046
Description
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cutting-edge immunotherapies. These novel treatments aim to address a range of serious conditions, including autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. This development is underpinned by a proprietary technological platform engineered to restore the body's immune system balance and re-establish overall physiological homeostasis. The company's therapeutic strategies are designed to directly stimulate patients' immune systems, specifically eliciting antigen-specific killer T-cells and antibodies to activate crucial defenses against inflammatory, infectious, and cancerous diseases. Statera BioPharma's clinical pipeline features programs such as STAT-201 for Crohn's disease, Entolimod for hematological conditions, STAT-401 for pancreatic cancer, and STAT-205 for COVID-19. The company is also actively exploring therapeutic applications for fibromyalgia and multiple sclerosis. Formerly known as Cytocom, Inc., the company officially adopted the name Statera BioPharma, Inc. in September 2021. Its operations are headquartered in Fort Collins, Colorado.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Cytocom, Inc. | CBLI | 2021-02-12 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4.1K
Beta
-4.78
Float Shares
48.11M
Free Float %
67.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -66.67% | +0.00% | -99.67% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-22.79
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%— Q3'22: +183.5% (vs Q3'21)
-
EPS growth Biotechnology: +29.7%-855.8% Q3'22: +78.7% (vs Q3'21)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q3'22: -119.5% (vs Q3'21)
-
EBIT margin Biotechnology: +0.0%— Q3'22: -230.6% (vs Q3'21)
-
ROIC Biotechnology: -16.1%-1,337.8% Q3'22: +189.3% (vs Q3'21)
-
Share dilution Biotechnology: -3.4%+36.9% Q3'22: +85.8% (vs Q3'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.10× Q3'22: -1.37× (vs Q3'21)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.80M
OE per share TTM
-1.11
Owner's Yield
-135,414.93%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mikhail Mogutov, Ph.D. | 7.93M | 13.27% | 7.93M | — | 7.93M | 10.00 | IN | Russian Federation | 2014-07-02 | ↗ |
| 2 | Sabby Healthcare Volatility Master Fund, Ltd. | 5.09M | 9.99% | — | 5.09M | — | 5.09M | CO | Cayman Islands | 2014-01-14 | ↗ |
| 3 | Andrei Gudkov | 1.78M | 6.10% | — | — | — | — | IN | United States America | 2011-02-04 | ↗ |
| 4 | Gudkov | 1.70M | 8.40% | 1.70M | — | 1.70M | — | IN | States of America | 2010-02-11 | ↗ |
| 5 | Michael Fonstein | 1.70M | 4.70% | 1.70M | — | 1.70M | — | IN | Russian Federation | 2012-03-21 | ↗ |
| 6 | ABOVE PERSONS ( | 1.62M | 11.00% | — | 1.47M | 150.0K | 1.47M | IN | United States of America | 2009-11-05 | ↗ |
| 7 | The Cleveland Clinic Foundation | 1.34M | 11.30% | 1.34M | — | 1.34M | — | CO | Ohio | 2007-02-14 | ↗ |
| 8 | James W. Harpel | 1.21M | 9.00% | 1.01M | 196.0K | 1.01M | 196.0K | IN | — | 2021-02-11 | ↗ |
| 9 | Sunrise Equity Partners, LP | 1.19M | 10.03% | 1.19M | — | 1.19M | — | PN | Delaware | 2007-01-19 | ↗ |
| 10 | Kogan | 866.0K | 4.20% | 866.0K | — | 866.0K | — | IN | Federation | 2010-02-11 | ↗ |
| 11 | Yakov Kogan | 715.2K | 6.00% | 715.2K | — | 715.2K | — | IN | United States of America | 2007-02-14 | ↗ |
| 12 | ChemBridge Corporation | 622.2K | 5.10% | 622.2K | — | 622.2K | — | CO | Illinois | 2007-02-27 | ↗ |
| 13 | Eugene Vaisberg | 622.2K | 5.10% | 622.2K | — | 622.2K | — | IN | United States of America | 2007-02-27 | ↗ |
| 14 | Fonstein | 546.0K | 5.30% | 1.55M | — | 546.0K | — | IN | Russian Federation | 2011-02-04 | ↗ |
| 15 | Armistice Capital Master Fund Ltd. | 519.2K | 3.90% | — | 519.2K | — | 519.2K | CO | Cayman Islands | 2020-06-11 | ↗ |
| 16 | Armistice Capital, LLC | 519.2K | 3.90% | — | 519.2K | — | 519.2K | IA, OO | Cayman Islands | 2020-06-11 | ↗ |
| 17 | Steven Boyd | 519.2K | 3.90% | — | 519.2K | — | 519.2K | HC, IN | Cayman Islands | 2020-06-11 | ↗ |
| 18 | Equity Partners, LP | 518.9K | 1.86% | 518.9K | — | 518.9K | — | PN | Delaware | 2011-02-14 | ↗ |
| 19 | Edward Quinn | 396.5K | 9.90% | — | — | 396.5K | — | IN | States | 2015-05-26 | ↗ |
| 20 | Alpha Capital Anstalt | 286.1K | 9.99% | 286.1K | — | 286.1K | — | EP, IN | Liechtenstein | 2015-02-05 | ↗ |
| 21 | Sunrise Securities Corp. | 250.6K | 2.10% | 250.6K | — | 250.6K | — | BD | New York | 2007-01-19 | ↗ |
| 22 | Capital Anstalt | 199.4K | 1.77% | 199.4K | — | 199.4K | — | CO | Liechtenstein | 2018-02-28 | ↗ |
| 23 | Securities Corp. | 128.7K | 0.47% | 128.7K | — | 128.7K | — | BD | York | 2011-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-22 | Chandrasekhar Satishchandran | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-09-28 | Markvicka Taunia | Director / Officer | A-Award | A | Common Stock, par value $0.005 per share | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2021-09-09 | Verny Lea | Director | A-Award | A | Common Stock, par value $0.005 per share | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2021-09-09 | SALUCK RANDY S. | Director | A-Award | A | Common Stock, par value $0.005 per share | 60,000 | 0.00 | — | 60,140 | — | ↗ |
| 2021-09-09 | Barbarick Steve K | Director | A-Award | A | Common Stock, par value $0.005 per share | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2021-07-27 | Selsky Clifford | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-27 | McAvoy Cozette M. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-27 | Markvicka Taunia | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-27 | Handley Michael K | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-27 | Buckheit Robert | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-27 | Barbarick Steve K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-27 | ARONSTAM PETER | Officer | A-Award | A | Common Stock, par value $0.005 per share | 141,370 | 0.00 | — | 141,370 | — | ↗ |
| 2021-07-22 | Miller Langdon L | Officer | M-Exempt | A | Common Stock, par value $0.005 per share | 10,000 | 3.00 | 30.0K | 10,000 | — | ↗ |
| 2018-08-10 | Fedyunin Ivan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-04-21 | Szydlo John Edward | Officer | — | D | Employee Stock Option (right to buy) | 1,200 | 3.20 | 3.8K | 0 | — | ↗ |
| 2016-07-21 | Talyanskiy Daniil | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-07-21 | SALUCK RANDY S. | Director | — | D | Stock Option (right to buy) | 750 | 36.40 | 27.3K | 0 | — | ↗ |
| 2016-07-21 | Andryushechkin Alexander | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-04-14 | Verny Lea | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-04-14 | Nechaev Alexey | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-09 | Zosh Christopher | Officer | — | D | Employee Stock Option (right to buy) | 125 | 10.40 | 1.3K | 0 | — | ↗ |
| 2015-07-09 | Saraeva Natalia | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-09 | Persiyanov Ivan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-09 | Levina Tatiana | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-09 | Lebedina Yulia | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-09 | Khudyk Natalia | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-09 | Gorshkov Konstantin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-07-09 | Evdokimova Anna | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-05-04 | Miller Langdon L | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 3.00 | 30.0K | 10,000 | — | ↗ |
| 2015-04-22 | SALUCK RANDY S. | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.20 | 51.2K | 16,000 | — | ↗ |
| 2015-04-22 | Principi Anthony | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.20 | 51.2K | 16,000 | — | ↗ |
| 2015-04-22 | McGowan Richard | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.20 | 51.2K | 16,000 | — | ↗ |
| 2015-04-22 | Lyons C Neil | Officer | A-Award | A | Stock Option (right to buy) | 6,250 | 3.20 | 20.0K | 6,250 | — | ↗ |
| 2015-04-22 | Kogan Yakov | Director / Officer | A-Award | A | Stock Option (right to buy) | 6,250 | 3.20 | 20.0K | 12,500 | — | ↗ |
| 2015-04-22 | Kasimova Elena | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.20 | 51.2K | 16,000 | — | ↗ |
| 2015-04-22 | Gudkov Andrei V | Director / Officer | A-Award | A | Stock Option (right to buy) | 6,250 | 3.20 | 20.0K | 6,250 | — | ↗ |
| 2015-04-22 | Antal James | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.20 | 51.2K | 16,000 | — | ↗ |
| 2015-02-25 | SALUCK RANDY S. | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 1,891 | 3.42 | 6.5K | 6,116 | — | ↗ |
| 2015-01-27 | Kasimova Elena | Director | A-Award | A | Stock Option (right to buy) | 750 | 4.80 | 3.6K | 750 | — | ↗ |
| 2015-01-08 | Principi Anthony | Director | A-Award | A | Common Stock | 37,947 | 0.30 | 11.4K | 52,419 | — | ↗ |
| 2015-01-08 | BROWN JULIA R | Director | A-Award | A | Common Stock | 62,500 | 0.30 | 18.8K | 116,482 | — | ↗ |
| 2014-12-31 | BROWN JULIA R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-09-29 | McGowan Richard | Director | A-Award | A | Series D Warrant | 264,286 | 0.51 | 133.5K | 264,286 | — | ↗ |
| 2014-06-20 | Mogutov Mikhail | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,286,344 | — | ↗ |
| 2014-06-11 | SALUCK RANDY S. | Director | A-Award | A | Stock Option (right to buy) | 1,750 | 9.80 | 17.2K | 1,750 | — | ↗ |
| 2014-06-11 | Principi Anthony | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.49 | 17.2K | 35,000 | — | ↗ |
| 2014-06-11 | Polinsky Alexander | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-06-11 | McGowan Richard | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.49 | 7.4K | 15,000 | — | ↗ |
| 2014-06-11 | Hoth Daniel Floyd JR | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-06-11 | BROWN JULIA R | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.49 | 17.2K | 35,000 | — | ↗ |
| 2014-06-11 | Antal James | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.49 | 17.2K | 35,000 | — | ↗ |
| 2014-03-13 | Lyons C Neil | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 0.68 | 102.0K | 150,000 | — | ↗ |
| 2014-03-13 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 0.68 | 102.0K | 150,000 | — | ↗ |
| 2014-03-13 | Hohn David C | Director | A-Award | A | Common Stock, par value $0.005 per share | 22,978 | 0.68 | 15.6K | 43,049 | — | ↗ |
| 2014-03-13 | Gudkov Andrei V | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 0.68 | 102.0K | 150,000 | — | ↗ |
| 2013-06-19 | Principi Anthony | Director | A-Award | A | Common Stock, par value $0.005 per share | 14,472 | 0.00 | — | 14,472 | — | ↗ |
| 2013-06-19 | Hohn David C | Director | A-Award | A | Common Stock, par value $0.005 per share | 10,487 | 0.00 | — | 20,071 | — | ↗ |
| 2013-06-19 | DiCorleto Paul E | Director | A-Award | A | Common Stock, par value $0.005 per share | 10,102 | 0.00 | — | 41,968 | — | ↗ |
| 2013-06-19 | BROWN JULIA R | Director | A-Award | A | Common Stock, par value $0.005 per share | 15,939 | 0.00 | — | 15,939 | — | ↗ |
| 2013-06-14 | SALUCK RANDY S. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.58 | 55.3K | 35,000 | — | ↗ |
| 2013-06-14 | Principi Anthony | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.58 | 55.3K | 35,000 | — | ↗ |
| 2013-06-14 | Hohn David C | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.58 | 55.3K | 35,000 | — | ↗ |
| 2013-06-14 | DiCorleto Paul E | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.58 | 55.3K | 35,000 | — | ↗ |
| 2013-06-14 | BROWN JULIA R | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.58 | 55.3K | 35,000 | — | ↗ |
| 2013-06-14 | Antal James | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 1.58 | 55.3K | 35,000 | — | ↗ |
| 2013-05-21 | DiCorleto Paul E | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 6,210 | 1.61 | 10.0K | 31,866 | — | ↗ |
| 2013-05-17 | SALUCK RANDY S. | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 3,500 | 1.60 | 5.6K | 84,500 | — | ↗ |
| 2013-05-13 | Lyons C Neil | Officer | A-Award | A | Employee Stock Option (right to buy) | 77,131 | 1.54 | 118.8K | 77,131 | — | ↗ |
| 2013-05-13 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 1.54 | 38.5K | 25,000 | — | ↗ |
| 2013-05-13 | Gudkov Andrei V | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 84,057 | 1.54 | 129.4K | 84,057 | — | ↗ |
| 2013-05-13 | Fonstein Michael | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 81,828 | 1.54 | 126.0K | 81,828 | — | ↗ |
| 2013-05-08 | SALUCK RANDY S. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.82 | 27.3K | 15,000 | — | ↗ |
| 2013-05-07 | SALUCK RANDY S. | Director | — | I | Common Stock Warrants (right to buy) | 25,000 | 3.00 | 75.0K | 0 | — | ↗ |
| 2013-04-22 | Principi Anthony | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.96 | 29.4K | 15,000 | — | ↗ |
| 2013-04-22 | BROWN JULIA R | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.96 | 29.4K | 15,000 | — | ↗ |
| 2013-04-03 | Viallet Jean | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.04 | 204.0K | 100,000 | — | ↗ |
| 2013-04-01 | Viallet Jean | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-03-15 | Antal James | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 3,700 | 1.56 | 5.8K | 8,000 | — | ↗ |
| 2012-12-31 | Kogan Yakov | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-12-31 | Antal James | Director | — | D | Common Stock, par value $0.005 per share | 0 | 0.00 | — | 27,258 | — | ↗ |
| 2012-11-28 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 21,812 | 1.28 | 27.9K | 21,812 | — | ↗ |
| 2012-10-25 | KASTEN BERNARD L | Director | A-Award | A | Stock Options (Right to Buy) | 100,000 | 1.45 | 145.0K | 100,000 | — | ↗ |
| 2012-09-21 | Antal James | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 2,316 | 2.60 | 6.0K | 27,258 | — | ↗ |
| 2012-07-02 | Hohn David C | Director | P-Purchase | A | Common stock, par value $0.005 per share | 1,000 | 1.61 | 1.6K | 9,584 | — | ↗ |
| 2012-06-26 | Lyons C Neil | Officer | A-Award | A | Common stock, par value $0.005 per share | 20,273 | 0.00 | — | 20,273 | — | ↗ |
| 2012-06-26 | Kogan Yakov | Director / Officer | A-Award | A | Common stock, par value $0.005 per share | 27,482 | 0.00 | — | 671,982 | — | ↗ |
| 2012-06-26 | KASTEN BERNARD L | Director | A-Award | A | Common stock, par value $0.005 per share | 6,342 | 0.00 | — | 26,998 | — | ↗ |
| 2012-06-26 | Hohn David C | Director | A-Award | A | Common stock, par value $0.005 per share | 5,584 | 0.00 | — | 8,584 | — | ↗ |
| 2012-06-26 | Gudkov Andrei V | Director / Officer | A-Award | A | Common stock, par value $0.005 per share | 12,770 | 0.00 | — | 1,517,370 | — | ↗ |
| 2012-06-26 | Fonstein Michael | Director / Officer | A-Award | A | Common stock, par value $0.005 per share | 8,065 | 0.00 | — | 1,176,465 | — | ↗ |
| 2012-06-15 | Antal James | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 3,400 | 1.76 | 6.0K | 24,942 | — | ↗ |
| 2012-06-13 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 100,000 | 1.79 | 179.0K | 100,000 | — | ↗ |
| 2012-06-13 | KASTEN BERNARD L | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 1.79 | 62.7K | 35,000 | — | ↗ |
| 2012-06-13 | Hohn David C | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 1.79 | 62.7K | 35,000 | — | ↗ |
| 2012-06-13 | DiCorleto Paul E | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 1.79 | 62.7K | 35,000 | — | ↗ |
| 2012-06-13 | Antal James | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 1.79 | 62.7K | 35,000 | — | ↗ |
| 2012-04-04 | Hohn David C | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 1,000 | 1.71 | 1.7K | 3,000 | — | ↗ |
| 2012-03-20 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock, par value $0.005 per share | 20,000 | 2.94 | 58.9K | 1,168,400 | — | ↗ |
| 2012-03-19 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock, par value $0.005 per share | 35,601 | 3.04 | 108.2K | 1,188,400 | — | ↗ |
| 2012-03-16 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock, par value $0.005 per share | 44,399 | 3.12 | 138.6K | 1,224,001 | — | ↗ |
| 2012-03-16 | Antal James | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 300 | 3.14 | 942.00 | 19,942 | — | ↗ |
| 2012-01-23 | Lyons C Neil | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 18,750 | 3.35 | 62.8K | 18,750 | — | ↗ |
| 2012-01-23 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 56,250 | 3.35 | 188.4K | 56,250 | — | ↗ |
| 2012-01-23 | Gudkov Andrei V | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 56,250 | 3.35 | 188.4K | 56,250 | — | ↗ |
| 2012-01-23 | Fonstein Michael | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 56,250 | 3.35 | 188.4K | 56,250 | — | ↗ |
| 2012-01-04 | Hohn David C | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 1,000 | 2.98 | 3.0K | 2,000 | — | ↗ |
| 2011-12-22 | McGowan Richard | Director | — | I | Series F Warrant | 25,000 | 5.00 | 125.0K | 0 | — | ↗ |
| 2011-12-16 | Antal James | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 1,040 | 2.79 | 2.9K | 18,877 | — | ↗ |
| 2011-11-17 | Kogan Yakov | Director / Officer | A-Award | A | Common Stock, par value $0.005 per share | 1,712 | 0.00 | — | 646,212 | — | ↗ |
| 2011-11-07 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 5,000 | 3.03 | 15.2K | 5,000 | — | ↗ |
| 2011-10-04 | Hohn David C | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 1,000 | 2.36 | 2.4K | 1,000 | — | ↗ |
| 2011-09-16 | Antal James | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 35 | 3.22 | 112.70 | 17,537 | — | ↗ |
| 2011-09-02 | Fonstein Michael | Director / Officer | P-Purchase | A | Common Stock, par value $0.005 per share | 2,200 | 2.27 | 5.0K | 1,253,400 | — | ↗ |
| 2011-09-01 | Lyons C Neil | Officer | — | D | Employee Stock Options (Right to Buy) | 125,000 | 2.41 | 301.3K | 0 | — | ↗ |
| 2011-08-19 | Kogan Yakov | Director / Officer | P-Purchase | A | Common Stock | 1,300 | 2.29 | 3.0K | 644,500 | — | ↗ |
| 2011-08-15 | KASTEN BERNARD L | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 5,000 | 2.58 | 12.9K | 222,656 | — | ↗ |
| 2011-08-15 | DiCorleto Paul E | Director | P-Purchase | A | Common Stock | 10,000 | 2.60 | 26.0K | 25,656 | — | ↗ |
| 2011-08-12 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 4,426 | 2.44 | 10.8K | 4,426 | — | ↗ |
| 2011-08-12 | KASTEN BERNARD L | Director | A-Award | A | Stock Options (Right to Buy | 35,000 | 2.44 | 85.4K | 35,000 | — | ↗ |
| 2011-08-12 | Hohn David C | Director | A-Award | A | Stock Options (Right to Buy | 35,000 | 2.44 | 85.4K | 35,000 | — | ↗ |
| 2011-08-12 | DiCorleto Paul E | Director | A-Award | A | Stock Options (Right to Buy | 35,000 | 2.44 | 85.4K | 35,000 | — | ↗ |
| 2011-08-12 | Antal James | Director | A-Award | A | Stock Options (Right to Buy | 35,000 | 2.44 | 85.4K | 35,000 | — | ↗ |
| 2011-06-07 | Hohn David C | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-05-12 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 2,213 | 7.31 | 16.2K | 2,213 | — | ↗ |
| 2011-03-21 | Marhofer John A Jr | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 149,609 | 7.16 | 1.07M | 149,609 | — | ↗ |
| 2011-03-21 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 149,609 | 7.16 | 1.07M | 149,609 | — | ↗ |
| 2011-03-21 | Gudkov Andrei V | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 149,609 | 7.16 | 1.07M | 149,609 | — | ↗ |
| 2011-03-21 | Fonstein Michael | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 149,609 | 7.16 | 1.07M | 149,609 | — | ↗ |
| 2011-03-18 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 2,128 | 7.39 | 15.7K | 4,255 | — | ↗ |
| 2010-11-19 | KASTEN BERNARD L | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 10,000 | 6.15 | 61.5K | 27,656 | — | ↗ |
| 2010-11-18 | KASTEN BERNARD L | Director | P-Purchase | A | Common Stock, par value $0.005 per share | 2,000 | 6.10 | 12.2K | 17,656 | — | ↗ |
| 2010-11-17 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 4,255 | 6.09 | 25.9K | 4,255 | — | ↗ |
| 2010-08-18 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 3,856 | 3.91 | 15.1K | 3,856 | — | ↗ |
| 2010-06-08 | Perez Hector Daniel | Director | A-Award | A | Common Stock | 8,389 | 0.00 | — | 12,749 | — | ↗ |
| 2010-06-08 | KASTEN BERNARD L | Director | A-Award | A | Common Stock | 8,389 | 0.00 | — | 15,656 | — | ↗ |
| 2010-06-08 | DiCorleto Paul E | Director | A-Award | A | Common Stock | 8,389 | 0.00 | — | 15,656 | — | ↗ |
| 2010-06-08 | Antal James | Director | A-Award | A | Common Stock | 8,389 | 0.00 | — | 15,656 | — | ↗ |
| 2010-05-18 | Perez Hector Daniel | Director | A-Award | A | Common Stock | 4,360 | 0.00 | — | 4,360 | — | ↗ |
| 2010-05-18 | Marhofer John A Jr | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 105,000 | 3.44 | 361.2K | 105,000 | — | ↗ |
| 2010-05-18 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 105,000 | 3.44 | 361.2K | 105,000 | — | ↗ |
| 2010-05-18 | KASTEN BERNARD L | Director | A-Award | A | Common Stock | 7,267 | 0.00 | — | 7,267 | — | ↗ |
| 2010-05-18 | Gudkov Andrei V | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 105,000 | 3.44 | 361.2K | 105,000 | — | ↗ |
| 2010-05-18 | Fonstein Michael | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 105,000 | 3.44 | 361.2K | 105,000 | — | ↗ |
| 2010-05-18 | DiCorleto Paul E | Director | A-Award | A | Common Stock | 7,267 | 0.00 | — | 7,267 | — | ↗ |
| 2010-05-18 | Antal James | Director | A-Award | A | Common Stock | 7,267 | 0.00 | — | 7,267 | — | ↗ |
| 2010-05-17 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 300 | 3.62 | 1.1K | 1,505,190 | — | ↗ |
| 2010-05-03 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 500 | 3.76 | 1.9K | 665,200 | — | ↗ |
| 2010-04-22 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 200 | 3.91 | 782.00 | 1,269,900 | — | ↗ |
| 2010-04-16 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 200 | 3.59 | 718.00 | 1,514,400 | — | ↗ |
| 2010-04-01 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 100 | 3.51 | 351.00 | 669,437 | — | ↗ |
| 2010-03-22 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 2,334 | 3.58 | 8.4K | 1,272,600 | — | ↗ |
| 2010-03-16 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 500 | 3.64 | 1.8K | 1,518,800 | — | ↗ |
| 2010-03-01 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 200 | 3.82 | 764.00 | 674,300 | — | ↗ |
| 2010-02-22 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 1,000 | 3.87 | 3.9K | 1,280,200 | — | ↗ |
| 2010-02-16 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 2,000 | 3.90 | 7.8K | 1,521,700 | — | ↗ |
| 2010-02-01 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 300 | 3.96 | 1.2K | 684,900 | — | ↗ |
| 2010-01-22 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 600 | 3.97 | 2.4K | 1,285,600 | — | ↗ |
| 2010-01-19 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 300 | 3.91 | 1.2K | 1,528,400 | — | ↗ |
| 2010-01-04 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 5,800 | 3.50 | 20.3K | 685,400 | — | ↗ |
| 2009-12-30 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 751 | 3.55 | 2.7K | 1,529,800 | — | ↗ |
| 2009-12-30 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 200 | 3.60 | 720.00 | 1,286,200 | — | ↗ |
| 2009-12-23 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 4,049 | 3.50 | 14.2K | 1,530,551 | — | ↗ |
| 2009-12-23 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 4,049 | 3.50 | 14.2K | 1,287,151 | — | ↗ |
| 2009-12-01 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 4,800 | 3.75 | 18.0K | 692,400 | — | ↗ |
| 2009-11-23 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 400 | 3.57 | 1.4K | 1,295,800 | — | ↗ |
| 2009-11-16 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 100 | 3.85 | 385.00 | 1,537,900 | — | ↗ |
| 2009-11-02 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 500 | 3.90 | 2.0K | 699,900 | — | ↗ |
| 2009-10-22 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 700 | 4.22 | 3.0K | 1,300,300 | — | ↗ |
| 2009-10-16 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 100 | 4.77 | 477.00 | 1,544,500 | — | ↗ |
| 2009-10-01 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 200 | 4.16 | 832.00 | 708,100 | — | ↗ |
| 2009-09-22 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 300 | 3.93 | 1.2K | 1,305,600 | — | ↗ |
| 2009-09-16 | Gudkov Andrei V | Director / Officer | S-Sale | D | Common Stock | 400 | 4.10 | 1.6K | 1,549,200 | — | ↗ |
| 2009-09-01 | Kogan Yakov | Director / Officer | S-Sale | D | Common Stock | 100 | 3.84 | 384.00 | 709,200 | — | ↗ |
| 2009-08-24 | Fonstein Michael | Director / Officer | S-Sale | D | Common Stock | 700 | 4.37 | 3.1K | 1,310,500 | — | ↗ |
| 2009-06-25 | Perez Hector Daniel | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 3.33 | 116.6K | 120,000 | — | ↗ |
| 2009-06-25 | KASTEN BERNARD L | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 3.33 | 116.6K | 120,000 | — | ↗ |
| 2009-06-25 | DiCorleto Paul E | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 3.33 | 116.6K | 105,000 | — | ↗ |
| 2009-06-25 | Antal James | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 3.33 | 116.6K | 120,000 | — | ↗ |
| 2009-02-13 | McGowan Richard | Director | — | I | Series D Warrant | 200,000 | 1.22 | 244.0K | 0 | — | ↗ |
| 2008-04-29 | Perez Hector Daniel | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 5.88 | 205.8K | 85,000 | — | ↗ |
| 2008-04-29 | KASTEN BERNARD L | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 5.88 | 205.8K | 85,000 | — | ↗ |
| 2008-04-29 | DiCorleto Paul E | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 5.88 | 205.8K | 70,000 | — | ↗ |
| 2008-04-29 | Antal James | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 5.88 | 205.8K | 85,000 | — | ↗ |
| 2008-02-04 | Marhofer John A Jr | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 91,500 | 4.00 | 366.0K | 159,684 | — | ↗ |
| 2008-02-04 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 137,250 | 4.00 | 549.0K | 174,750 | — | ↗ |
| 2008-02-04 | Gudkov Andrei V | Director / Officer / 10% Owner | A-Award | A | Employee Stock Options (Right to Buy) | 137,250 | 4.00 | 549.0K | 174,750 | — | ↗ |
| 2008-02-04 | Fonstein Michael | Director / Officer / 10% Owner | A-Award | A | Employee Stock Options (Right to Buy) | 137,250 | 4.00 | 549.0K | 174,750 | — | ↗ |
| 2007-10-18 | SUNRISE SECURITIES CORP | 10% Owner | S-Sale | D | Common Stock | 5,000 | 12.02 | 60.1K | 0 | — | ↗ |
| 2007-10-17 | SUNRISE SECURITIES CORP | 10% Owner | S-Sale | D | Common Stock | 7,500 | 11.81 | 88.6K | 5,000 | — | ↗ |
| 2007-10-16 | SUNRISE SECURITIES CORP | 10% Owner | S-Sale | D | Common Stock | 7,850 | 11.61 | 91.1K | 12,500 | — | ↗ |
| 2007-10-15 | SUNRISE SECURITIES CORP | 10% Owner | S-Sale | D | Common Stock | 5,000 | 11.91 | 59.6K | 20,350 | — | ↗ |
| 2007-06-12 | Perez Hector Daniel | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 9.40 | 329.0K | 35,000 | — | ↗ |
| 2007-06-12 | KASTEN BERNARD L | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 9.40 | 329.0K | 50,000 | — | ↗ |
| 2007-06-12 | DiCorleto Paul E | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 9.40 | 329.0K | 35,000 | — | ↗ |
| 2007-06-12 | Antal James | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 9.40 | 329.0K | 50,000 | — | ↗ |
| 2007-04-06 | Marhofer John A Jr | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 25,000 | 8.36 | 209.0K | 25,000 | — | ↗ |
| 2007-04-06 | Kogan Yakov | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 37,500 | 8.36 | 313.5K | 37,500 | — | ↗ |
| 2007-04-06 | Gudkov Andrei V | Director / Officer / 10% Owner | A-Award | A | Employee Stock Options (Right to Buy) | 37,500 | 8.36 | 313.5K | 37,500 | — | ↗ |
| 2007-04-06 | Fonstein Michael | Director / Officer / 10% Owner | A-Award | A | Employee Stock Options (Right to Buy) | 37,500 | 8.36 | 313.5K | 37,500 | — | ↗ |
| 2006-08-11 | Cleveland Clinic Foundation | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,341,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
71.42M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Michael K. Handley President and Chief Executive Officer | 540.0K | — | — | — | — | 2.33M | 2.87M | 0.00% | ↗ |
| 2 | 2021 | Noreen Griffin Former President | 440.0K | — | — | — | — | 1.90M | 2.34M | 0.00% | ↗ |
| 3 | 2021 | Cozette McAvoy Former Chief Legal Officer | 381.7K | — | — | — | — | 582.0K | 963.7K | 0.00% | ↗ |
| 4 | 2021 | Peter Aronstam Former Chief Financial Officer | 312.5K | — | — | — | — | 543.6K | 856.1K | 0.00% | ↗ |
| 5 | 2020 | Michael K. Handley President and Chief Executive Officer | 252.5K | — | — | — | — | 158.5K | 411.0K | 0.00% | ↗ |
| 6 | 2020 | Noreen Griffin Former President | 223.3K | — | — | — | — | 110.0K | 333.3K | 0.00% | ↗ |
| 7 | 2020 | Cozette McAvoy Former Chief Legal Officer | 181.7K | — | — | — | — | 96.9K | 278.5K | 0.00% | ↗ |
| 8 | 2020 | Peter Aronstam Former Chief Financial Officer | 145.8K | — | — | — | — | 106.3K | 252.1K | 0.00% | ↗ |
| 9 | 2020 | Christopher Zosh Vice President of Finance (principal executive officer and principal financial officer) | 116.8K | — | — | — | — | 4.7K | 121.4K | 0.00% | ↗ |
| 10 | 2020 | Andrei Gudkov Chief Science Officer | 26.1K | — | — | — | — | — | 26.1K | 0.00% | ↗ |
| 11 | 2020 | Langdon L. Miller Chief Medical Officer | 23.1K | — | — | — | — | — | 23.1K | 0.00% | ↗ |
| 12 | 2019 | Yakov Kogan Former Chief Executive Officer | 264.3K | — | — | — | — | 50.6K | 314.9K | 0.00% | ↗ |
| 13 | 2019 | Christopher Zosh Vice President of Finance (principal executive officer and principal financial officer) | 92.5K | — | — | — | — | 11.0K | 103.5K | 0.00% | ↗ |
| 14 | 2019 | Christopher Zosh Vice President of Finance | 92.5K | — | — | — | — | 11.0K | 103.5K | 0.00% | ↗ |
| 15 | 2019 | Langdon L. Miller Chief Medical Officer | 73.7K | — | — | — | — | — | 77.6K | 0.00% | ↗ |
| 16 | 2019 | Andrei Gudkov Chief Science Officer | 66.1K | — | — | — | — | — | 66.1K | 0.00% | ↗ |
| 17 | 2018 | Yakov Kogan Chief Executive Officer | 276.0K | — | — | — | — | 10.8K | 286.8K | 0.00% | ↗ |
| 18 | 2018 | Yakov Kogan Former Chief Executive Officer | 276.0K | — | — | — | — | 10.8K | 286.8K | 0.00% | ↗ |
| 19 | 2018 | Langdon L. Miller President | 119.6K | — | — | — | — | — | 119.6K | 0.00% | ↗ |
| 20 | 2018 | Langdon L. Miller Chief Medical Officer | 119.6K | — | — | — | — | — | 119.6K | 0.00% | ↗ |
| 21 | 2018 | Andrei Gudkov Chief Science Officer | 110.9K | — | — | — | — | — | 110.9K | 0.00% | ↗ |
| 22 | 2018 | Christopher Zosh Vice President of Finance | 73.0K | — | — | — | — | 9.2K | 82.2K | 0.00% | ↗ |
| 23 | 2017 | Yakov Kogan Chief Executive Officer | 276.0K | — | — | — | — | 10.8K | 286.8K | 0.00% | ↗ |
| 24 | 2017 | Langdon L. Miller President | 233.4K | — | — | — | — | — | 233.4K | 0.00% | ↗ |
| 25 | 2017 | Andrei Gudkov Chief Science Officer | 110.9K | — | — | — | — | — | 110.9K | 0.00% | ↗ |
| 26 | 2016 | C. Neil Lyons Chief Financial Officer | 337.1K | — | — | — | — | 5.1K | 342.2K | 0.00% | ↗ |
| 27 | 2016 | Yakov Kogan Chief Executive Officer | 276.9K | — | — | — | — | 10.6K | 287.5K | 0.00% | ↗ |
| 28 | 2016 | Langdon L. Miller President | 193.6K | — | — | — | — | — | 193.6K | 0.00% | ↗ |
| 29 | 2016 | Andrei Gudkov Chief Science Officer | 110.9K | — | — | — | — | — | 110.9K | 0.00% | ↗ |
| 30 | 2015 | Langdon L. Miller President | 384.7K | — | — | 19.2K | — | — | 403.6K | 4.76% | ↗ |
| 31 | 2015 | C. Neil Lyons Chief Financial Officer | 285.9K | — | — | 12.4K | — | 10.3K | 308.6K | 4.01% | ↗ |
| 32 | 2015 | Yakov Kogan Chief Executive Officer | 277.0K | — | — | 12.4K | — | 10.2K | 299.6K | 4.13% | ↗ |
| 33 | 2014 | Yakov Kogan Chief Executive Officer | 302.3K | — | — | 62.2K | — | 10.0K | 374.5K | 16.60% | ↗ |
| 34 | 2014 | C. Neil Lyons Chief Financial Officer | 283.2K | — | — | 62.2K | — | 10.0K | 355.4K | 17.49% | ↗ |
| 35 | 2014 | Langdon L. Miller President | 338.3K | — | — | — | — | — | 338.3K | 0.00% | ↗ |
| 36 | 2014 | Andrei Gudkov Chief Scientific Officer | 119.3K | — | — | 62.2K | — | — | 181.4K | 34.26% | ↗ |
| 37 | 2013 | Michael Fonstein President | 315.1K | — | — | 95.4K | — | 205.7K | 616.1K | 15.48% | ↗ |
| 38 | 2013 | Yakov Kogan Chief Executive Officer | 407.6K | — | — | 121.9K | — | 10.0K | 539.5K | 22.59% | ↗ |
| 39 | 2013 | Jean Viallet Chief Development Officer | 265.2K | — | — | 140.5K | — | 61.0K | 466.8K | 30.11% | ↗ |
| 40 | 2013 | C. Neil Lyons Chief Financial Officer | 255.5K | — | — | 89.9K | — | 10.0K | 355.4K | 25.30% | ↗ |
| 41 | 2013 | Andrei Gudkov Chief Scientific Officer | 215.3K | — | — | 98.0K | — | — | 313.3K | 31.27% | ↗ |
| 42 | 2012 | Yakov Kogan Chief Executive Officer | 395.4K | — | — | 253.4K | — | 19.4K | 668.2K | 37.92% | ↗ |
| 43 | 2012 | Michael Fonstein President | 388.7K | — | — | 129.2K | — | 22.7K | 540.6K | 23.89% | ↗ |
| 44 | 2012 | Andrei Gudkov Chief Scientific Officer | 222.2K | — | — | 129.2K | — | — | 351.4K | 36.76% | ↗ |
| 45 | 2012 | C. Neil Lyons Chief Financial Officer | 255.5K | — | — | 43.1K | — | 5.5K | 304.1K | 14.16% | ↗ |
| 46 | 2011 | Michael Fonstein President and Chief Executive Officer in 2011 (current President) | 385.3K | — | — | — | 30.2K | — | 1.17M | 0.00% | ↗ |
| 47 | 2011 | Michael Fonstein President | 385.3K | — | — | 743.6K | 30.2K | 378.00 | 1.16M | 64.13% | ↗ |
| 48 | 2011 | Yakov Kogan Chief Executive Officer | 312.0K | — | — | 743.6K | 23.6K | 10.9K | 1.09M | 68.22% | ↗ |
| 49 | 2011 | Yakov Kogan Chief Operating Officer and Secretary in 2011 (current Interim Chief Executive Officer and Chief Operating Officer) | 312.0K | — | — | 743.6K | 23.6K | 10.9K | 1.09M | 68.22% | ↗ |
| 50 | 2011 | John A. Marhofer, Jr. Former Chief Financial Officer | 110.0K | — | — | — | — | 9.8K | 1.06M | 0.00% | ↗ |
| 51 | 2011 | Andrei Gudkov Chief Scientific Officer | 184.9K | — | — | 743.6K | 24.5K | — | 952.9K | 78.03% | ↗ |
| 52 | 2011 | C. Neil Lyons Current Chief Financial Officer | 83.3K | — | — | — | 7.5K | 15.7K | 318.2K | 0.00% | ↗ |
| 53 | 2011 | C. Neil Lyons Chief Financial Officer | 83.3K | — | — | 217.5K | 7.5K | 2.5K | 310.9K | 69.96% | ↗ |
| 54 | 2010 | Michael Fonstein President and Chief Executive Officer | 303.3K | — | — | 252.0K | 76.6K | 11.1K | 643.0K | 39.19% | ↗ |
| 55 | 2010 | Michael Fonstein President and Chief Executive Officer in 2011 (current President) | 303.3K | — | — | — | 76.6K | 1.8K | 643.0K | 0.00% | ↗ |
| 56 | 2010 | Michael Fonstein President | 303.3K | — | — | 252.0K | 76.6K | — | 631.9K | 39.88% | ↗ |
| 57 | 2010 | Yakov Kogan Chief Operating Officer | 259.2K | — | — | 252.0K | 59.8K | 9.5K | 580.6K | 43.40% | ↗ |
| 58 | 2010 | Yakov Kogan Chief Operating Officer and Secretary in 2011 (current Interim Chief Executive Officer and Chief Operating Officer) | 259.2K | — | — | — | 59.8K | — | 580.6K | 0.00% | ↗ |
| 59 | 2010 | Yakov Kogan Chief Executive Officer | 259.2K | — | — | 252.0K | 59.8K | 9.1K | 580.2K | 43.43% | ↗ |
| 60 | 2010 | John A. Marhofer, Jr. Former Chief Financial Officer | 216.1K | — | — | — | 50.3K | — | 511.7K | 0.00% | ↗ |
| 61 | 2010 | John A. Marhofer, Jr. Chief Financial Officer | 201.8K | — | — | 252.0K | 50.3K | 7.6K | 511.7K | 49.25% | ↗ |
| 62 | 2010 | Andrei Gudkov Chief Scientific Officer | 143.2K | — | — | 252.0K | 62.2K | — | 457.4K | 55.09% | ↗ |
| 63 | 2010 | C. Neil Lyons Current Chief Financial Officer | — | — | — | 252.0K | — | — | 252.0K | 100.00% | ↗ |
| 64 | 2009 | Michael Fonstein President and Chief Executive Officer in 2011 (current President) | 235.0K | — | — | 743.6K | 74.0K | — | 320.2K | 232.21% | ↗ |
| 65 | 2009 | Michael Fonstein President and Chief Executive Officer | 235.0K | — | — | — | 74.0K | 11.2K | 320.2K | 0.00% | ↗ |
| 66 | 2009 | Yakov Kogan Chief Operating Officer | 217.7K | — | — | — | 68.6K | 1.8K | 288.1K | 0.00% | ↗ |
| 67 | 2009 | Yakov Kogan Chief Operating Officer and Secretary in 2011 (current Interim Chief Executive Officer and Chief Operating Officer) | 217.7K | — | — | 252.0K | 68.6K | 9.5K | 288.1K | 87.48% | ↗ |
| 68 | 2009 | John A. Marhofer, Jr. Former Chief Financial Officer | 201.8K | — | — | 743.6K | 52.2K | — | 224.2K | 331.68% | ↗ |
| 69 | 2009 | John A. Marhofer, Jr. Chief Financial Officer | 165.9K | — | — | — | 52.2K | 6.1K | 224.2K | 0.00% | ↗ |
| 70 | 2009 | Yakov Kogan Chief Operating Officer and Secretary | 217.7K | — | — | — | — | — | 217.7K | 0.00% | ↗ |
| 71 | 2009 | Andrei Gudkov Chief Scientific Officer | 143.2K | — | — | — | 69.3K | — | 179.3K | 0.00% | ↗ |
| 72 | 2009 | C. Neil Lyons Current Chief Financial Officer | — | — | — | — | — | 11.1K | 11.1K | 0.00% | ↗ |
| 73 | 2008 | Michael Fonstein President and Chief Executive Officer | 243.6K | — | — | 354.1K | — | 12.2K | 609.9K | 58.06% | ↗ |
| 74 | 2008 | Yakov Kogan Chief Operating Officer | 217.7K | — | — | 354.1K | — | 7.4K | 579.1K | 61.14% | ↗ |
| 75 | 2008 | Yakov Kogan Chief Operating Officer and Secretary | 217.7K | — | — | 354.1K | — | 3.8K | 575.5K | 61.52% | ↗ |
| 76 | 2008 | Andrei Gudkov Chief Scientific Officer | 114.2K | — | — | 354.1K | — | — | 468.3K | 75.61% | ↗ |
| 77 | 2008 | John A. Marhofer, Jr. Chief Financial Officer | 165.9K | — | — | 236.1K | — | 5.2K | 407.1K | 57.99% | ↗ |
| 78 | 2008 | Michael Fonstein Chief Executive Officer | 243.6K | — | — | — | — | 12.2K | 255.8K | 0.00% | ↗ |
| 79 | 2007 | Yakov Kogan Chief Operating Officer and Secretary | 180.0K | 97.6K | — | 198.4K | — | 181.4K | 657.4K | 30.18% | ↗ |
| 80 | 2007 | Michael Fonstein Chief Executive Officer | 230.2K | 104.5K | — | 198.4K | — | 22.0K | 555.1K | 35.73% | ↗ |
| 81 | 2007 | John A. Marhofer, Jr. Chief Financial Officer | 133.3K | 83.9K | — | 152.4K | — | 7.8K | 377.4K | 40.37% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Blake Hawley | Executive Chairman | — | — |
| Christopher Zosh | Executive Vice President of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for STAB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
